Butyrate attenuates intestinal inflammation in Crohn’s disease by suppressing pyroptosis of intestinal epithelial cells via the cGSA-STING-NLRP3 axis
International Immunopharmacology · 2024-12 · 143 · 113305
DOI: 10.1016/j.intimp.2024.113305 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-12. Verfasst von Xiaofang Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Crohn Disease, Pyroptosis, Membrane Proteins. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
Butyrate can strengthen the intestinal epithelial barrier. However, the mechanisms by which butyrate affects intestinal epithelial cells (IECs) pyroptosis in Crohn's disease (CD) remain unclear. In this study, we collected colonic biopsy samples from CD patients and healthy controls to assess pyroptosis levels. Our findings indicated elevated expression of pyroptosis markers in CD patients, alongside distinct morphological evidence of pyroptosis in IECs. We further investigated the effects of tributyrin on pyroptosis and the cGAS-STING pathway in a trinitrobenzene sulfonic acid-induced colitis rat model. Tributyrin significantly mitigated intestinal inflammation, reduced pathological progression, and inhibited pyroptosis and cGAS-STING pathway activation in the colitis rat model. Similarly, in an in vitro model of IECs pyroptosis, sodium butyrate inhibited pyroptosis and cGAS-STING pathway activation in HT-29 cells. Co-treatment with a cGAS-STING pathway activator and butyrate demonstrated that the activator reversed the inhibitory effects of butyrate on pyroptosis and cGAS-STING pathway activation in both the colitis rat model and HT-29 cells. Mechanistically, the cGAS-STING pathway was found to interact with NLRP3. Taken together, butyrate may mitigate intestinal inflammation in CD by suppressing cGAS-STING-NLRP3 axis-mediated IECs pyroptosis. These findings offer new insights into potential therapeutic strategies for managing CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Emergency, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Clinical Experimental Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Electronic address: lxxp58@hotmail.com.
Zitieren
APA
Xu, X., Huang, Z., Huang, Z., Lv, X., Jiang, D., Huang, Z., Han, B., Lin, G., Liu, G., Li, S., Fan, J., & Lv, X. (2024). Butyrate attenuates intestinal inflammation in Crohn’s disease by suppressing pyroptosis of intestinal epithelial cells via the cGSA-STING-NLRP3 axis. International Immunopharmacology, 143, 113305. https://doi.org/10.1016/j.intimp.2024.113305
Vancouver
Xu X, Huang Z, Huang Z, Lv X, Jiang D, Huang Z, et al. Butyrate attenuates intestinal inflammation in Crohn’s disease by suppressing pyroptosis of intestinal epithelial cells via the cGSA-STING-NLRP3 axis. International Immunopharmacology. 2024;143:113305. doi:10.1016/j.intimp.2024.113305
BibTeX
@article{Xu2024,
author = {Xu, Xiaofang and Huang, Zhou and Huang, Zhixi and Lv, Xiaodan and Jiang, Dan and Huang, Ziqian and Han, Bing and Lin, Guangfu and Liu, Gengfeng and Li, Shiquan and Fan, Junhua and Lv, Xiaoping},
title = {Butyrate attenuates intestinal inflammation in Crohn’s disease by suppressing pyroptosis of intestinal epithelial cells via the cGSA-STING-NLRP3 axis},
journal = {International Immunopharmacology},
year = {2024},
volume = {143},
pages = {113305},
doi = {10.1016/j.intimp.2024.113305}
}
EUVIMED